median nerve) with lesions of the proximal segments (F-wave latency 62-ms on stimulating the tibial nerve at the ankle). There was a pronounced and widespread axonal degeneration, reflected in the small amplitude of the muscle and nerve potentials in nerve conduction velocity studies, and profuse fibrillations or positive sharp waves in muscles at rest on the electromyogram. These findings were compatible with a polyneuritis with severe axonal loss. Subsequent progress has been disappointingly slow, and the patient has been confined to a wheelchair for eight months since the onset.
Comment
The initial gastrointestinal illness with bloody stools suggested a Campylobacter infection; this was confirmed by the high antibody titre and by stool culture, which grew a Campylobacter species at high temperatures to identify it as one of the C colilC jejuni group. The subsequent neurological illness was consistent with a clinical diagnosis of the Guillain-Barre syndrome.' Though this syndrome may follow a gastrointestinal illnessl 2 an organism is rarely isolated from the stools, though a Salmonella species was found in two cases.3 Sixteen cases of Guillain-Barre syndrome occurred after an outbreak of water pollution, in which 5000 people had diarrhoea but no definite causative organism was found.5 So far as we are aware no case has been reported after Campylobacter infection. In our patient the Guillain-Barre syndrome occurred two weeks after the initial infection. This interval is similar to that seen after other gastrointestinal illnesses and suggests that the Guillain-Barre syndrome was triggered by the infection. There is no report of this syndrome occurring with any of the drugs he had received. Since Campylobacter infections have been recognised only in recent years, and the organism may be difficult to isolate from the stools, previous cases of Campylobacter infection associated with the Guillain-Barre syndrome may have been missed. Serum antibody titres to Campylobacter may help to resolve this in future cases of the Guillain-Barre syndrome associated with a gastrointestinal illness. Five years later the patient presented with haematuria followed three weeks later by extensive soft-tissue haemorrhage in both arms after minor trauma. Investigations showed partial thromboplastin time 99 s (control 52 s) and whole-blood clotting time 37 min (normal 4-9 min). Prothrombin time, bleeding time, thrombin time, platelet count, and fibrin degradation products were normal. Full blood count showed a normochromic normocytic anaemia, haemoglobin concentration 10 g/dl, white cell count 15X 109/1 (98% neutrophils, 2% lymphocytes), and a normal platelet count. Factor VIII was undetectable and high-titre inhibitor to factor VIII was present. Antinuclear factor titre was positive at 1/100, C4 concentration was reduced, LE cells were not detected, and all immunoglobulin values had fallen compared with before (IgM 2-9 g/l, IgA 0-6 g/l, IgG 4 2 g/l). (DNA binding was not tested initially but was subsequently found to be normal.
Prednisolone 30 mg daily produced no improvement. Cyclophosphamide was added but discontinued after two months as bruising and bleeding persisted. Between 1973 and 1978 prednisolone 2-5 mg daily was continued for her asthma. Her course was punctuated by recurrent haemarthroses, haematomas, epistaxes, and on one occasion by life-threatening retropharyngeal bleeding, which responded to intensive plasmapheresis and cryoprecipitate treatment.
In 1979 herpes zoster developed, followed by widespread varicella. The blood count was normal, haemoglobin concentration 13-0 g/dl, white cell count 7 4x 109/1 (76% neutrophils, 16% lymphocytes, 8% monocytes), and platelet count 270 X 109/1. Analysis of the surface membrane showed a normal total lymphocyte count with normal proportions of T and B lymphocytes and no evidence of monoclonal expansion, but there was gross impairment of lymphocyte transformation in response to pokeweed mitogen and phytohaemagglutinin. The 
Acquired factor VIII inhibitor has been reported in association with non-Hodgkin's lymphoma4 and myeloma5 but not with chronic lymphatic leukaemia. In our patient the temporal sequence was reversed; overt chronic lymphatic leukaemia occurred many years after the presenting illness and its appearance seemed to parallel an improvement in her coagulopathy. 
Patients, methods, and results
Seven patients with active hydatid disease were studied; all were being treated with mebendazole 50 mg/kg/day in divided doses, and five were undergoing elective surgery. It has been recommended that mebendazole is taken with meals, as concomitant fat ingestion may improve its poor absorption. In the two patients not undergoing operation the last dose of mebendazole was given with food; in the remaining patients the last dose before sampling was given before operation without food. All patients had been treated for one week before sampling. Samples of serum and cyst fluid were taken four hours after drug ingestion (during operation in five patients undergoing surgery). The serum and cyst fluid was frozen and transported to Belgium for measurement of drug concentrations. The technique used antibody to mebendazole produced in rabbits by repeated injection of the mebendazole derivative chemically coupled to bovine serum albumin.5
This method allows assay of plasma concentrations of mebendazole as low as 100 ng/l. Serum concentrations were mostly between 10 and 20 fig/l, and cyst concentrations were even lower, on average being below 1 Ixg/l (see table) . One patient (case No 5) with very high serum and cyst concentrations in fact had a simple hepatic cyst that was misdiagnosed as a hydatid.
Flubendazole is a related benzimidazole compound that is available as a sterile suspension and thus would seem to have an advantage over oral mebendazole, which is extremely insoluble and is thus poorly absorbed. This suspension was administered subcutaneously to 10 white female rats at 100 mg/kg/day at various intervals. The rats were exsanguinated four hours after dose, and flubendazole concentrations measured using technique as described for mebendazole. At one week a concentration of only 2-2 Hg/l was achieved rising to 6-4 Hg/l after two weeks, 13-4 ,eg/l after three, and 12-4 ,g/l after four. The gradual rise in flubendazole concentration is due to the slow release of the drug from the injected suspension, which is known to occur over at least five days. This is considerably different from the pharmacokinetics of orally administered mebendazole, the half life of which is around four hours.
Comment
Though this is a small study, the serum concentrations of flubendazole achieved are not encouraging. 
Case reports
Case 1-A 37-year-old woman had injured her left knee, rupturing the anterior cruciate ligament, when aged 16. From the age of 28 she had suffered repeated attacks of synovitis of the left knee. The synovial fluid contained numerous crystals typical of calcium pyrophosphate dihydrate on polarised light microscopy, and a radiographic joint survey showed linear chondrocalcinosis in the menisci of the left knee. There was no family history of arthritis, and metabolic screening for the known associations of chondrocalcinosis yielded negative results.
Case 2-A 48-year-old man with peroneal muscular atrophy, causing instability of the ankles, presented with acute synovitis of his right ankle. Synovial fluid was aspirated and contained pyrophosphate crystals. Radiographic screening showed chondrocalcinosis in both ankles and mid-tarsal joints but nowhere else. His-other joints remained clinically normal; there was no family history of arthritis and no metabolic abnormality to account for the chrondrocalcinosis.
Case 3-A 36-year-old womtan presented with pain at the base of her
